Lung Transplant for Refractory Lung-Limited Stage IV Non-Small Cell Lung Cancer.

Lung transplant for lung-limited stage IV NSCLC resulted in 100% one-year survival in selected patients, significantly outperforming medical management alone.

• Why it matters: Patients with refractory, lung-limited stage IV NSCLC often face death from respiratory failure, and effective treatment options are limited, creating a critical need for improved interventions.
• What they did: A prospective study of 98 adults with lung-limited stage IV NSCLC compared outcomes between 17 who received lung transplants and 81 who received medical management, with additional comparison to 306 lung transplant recipients without cancer.
• The result: Early posttransplant survival was excellent, with 100% at one year for NSCLC patients, suggesting lung transplant may offer a viable treatment pathway, though longer-term data are necessary.